

INDEX

	Paragraph	Page
ABC-M8 Chemical Agent Detector Paper	1-8	1-3
AC. (See Hydrogen cyanide.)		
Acetylcholine	1-4, 2-4a, 2-8a, 2-19a, 3-1c	1-2, 2-2, 2-9, 2-16, 3-1
Aerosols	1-3, 1-8b, 7-1 and -3, 7-9	1-1, 1-4, 7-1, 7-4
Air, land, and naval operations, disposal of contaminated clothing and equipment	B-5	B-1
Airtight plastic bags	B-5	B-1
Airway obstruction, treatment	2-4c and g, 2-6e, 2-16b, C-4b	2-6, 2-8, 2-14, C-1
Alcohol	3-2b, table 3-1	3-1, 3-2
Ammonia		
occurrence in military operations	10-5b	10-2
pathology	10-5c	10-2
physical properties	10-5a	10-2
prognosis	10-5f	10-2
symptoms	10-5d	10-2
treatment	10-5e	10-2
Amphetamines	3-1c, 3-4c	3-1, 3-3
Analeptics	5-9b	5-2
Analgesics	4-7b(2)(c)	4-3
Anemia	4-10a(2), 4-16a, 4-21a	4-10, 4-14, 4-16
Anoxia	6-7	6-2
Antibacterial therapy	4-7b, 4-8h	4-3, 4-9
Anticholinesterase	2-1d(1), table 3-1, 3-4a	2-1, 3-2, 3-3
Anticonvulsant drugs	2-4c(3), 2-6c, 2-8a(3) and b(3), 2-8c(3) and -9e, 2-9h, 2-12c and -14, 2-15c and -16c, app E	2-5, 2-8, 2-9, 2-11, 2-12, 2-13, 2-14, E-1
Antidote(s) for nerve agents	2-6—2-14	2-8
administration of	2-9, 2-11, 2-12, 2-15 and -16, 2-17 and -18, E-1	2-11, 2-12, 2-13, 2-14, 2-15, E-1
Antihistamines	5-9b	5-2
Anxiety reactions	table 3-1	3-2
Aplasia	4-16a	4-14
Arsenical vesicants		
characteristics	4-17	4-14
physical properties	4-17	4-14
physiological effects	4-18—4-21	4-14—4-16
treatment	4-17—4-21	4-14—4-16
Arsenoxides	4-17	4-14
Aspirin	7-16	7-4
Assisted ventilation		
administration	2-4c, 2-4g, 2-6f, 2-9h, 2-16b, 2-16g, 2-23b, 6-10, 10-5e	2-2, 2-6, 2-8, 2-12, 2-14, 2-15, 2-18, 6-2, 10-2
mechanical ventilator	2-16g	2-15
Atelectasis	5-4	5-1
Atropine sulfate. (See also Nerve agents.)		
administration by:		
autoinjector	2-10 and -11, 2-16a, 2-23a, E-2	2-12, 2-14, 2-18, E-1
atropine sulfate ophthalmic ointment (1 percent)	2-16d, 4-18b	2-15, 4-15
rate of absorption	2-8b	2-9

	Paragraph	Page
Atropine sulfate (<i>continued</i>)		
contraindications	5-9b	5-2
effects	2-7b, 2-8, 2-12	2-8, 2-9, 2-13
self-aid and buddy aid procedures	1-12, 2-11, 2-12, E-2, E-3	1-5, 2-12, 2-13, E-1, E-4
solution	4-7b	4-3
symptoms produced	2-8c	2-9
use with 2 PAM Cl	2-10, 2-15b, E-2m and -3n	2-12, 2-14, E-3
BAL ointment ((British anti-lewisite) dimercaprol)	4-19d(1), 4-21c	4-15, 4-16
Barbiturates	5-9b	5-2
Beclomethasone dipropionate	5-9e	5-2
Betamethasone	5-9e	5-2
Blankets, contaminated	4-3b, B-3, B-6	4-1, B-1, B-2
Bleach slurry	B-6 and -7	B-2
Blepharospasm	4-29b(3)(a), 7-4a(1)	4-18, 7-1
Blister agents. (<i>See also</i> Arsenical vesicants, Mustard, and Nitrogen mustard.)		
burns	4-1 and 4-6—4-31	4-1—4-22
characteristics	4-1 and -6	4-1
decontamination	4-3b, app B, app D	4-1, B-1, D-1
disposition of casualties		
cutaneous burns	4-31	4-19
eye injuries	4-29	4-18
evacuation of casualties	4-28d(1)(b), C-8	4-17, C-3
respiratory injuries	4-30	4-19
self-aid	4-2	4-1
Blood agents. (<i>See</i> Cyanogen chloride and Hydrogen cyanide.)		
Blister pack. (<i>See also</i> Nerve Agent Pyridostigmine Pretreatment Tablet Set.)	2-17 and -18, 2-20, 2-24a	2-15, 2-17, 2-18
Bromobenzylcyanide (CA)	7-1 and -3c, 7-4c, 7-5c and -7	7-1, 7-2, 7-3
Bronchiolar epithelium	5-4	5-1
Bronchitis	5-9d, 7-4a(1), 7-4c(1)	5-2, 7-1, 7-2
Bronchopneumonia	4-9b, 5-7 and -9d	4-10, 5-2
Buddy aid	1-12	1-5
Burns, treatment		
blister agents	4-7b, 4-8f, 4-12c, 4-18b and -19d	4-3, 4-8, 4-13, 4-15
incendiary agents	8-7e, 9-2 and -4b	8-3, 9-1
riot control agents	7-1	7-1
smokes	8-5e	8-2
Burow's solution	7-7b	7-3
BZ. (<i>See</i> Incapacitating agents.)		
Calamine lotion	7-7b	7-3
Cannabinols	3-1c and -2b, table 3-1, 3-4c	3-1, 3-2, 3-3
Carbon monoxide	10-2	10-1
poisoning		
diagnosis	10-2e	10-1
occurrence in military operations	10-2b	10-1
prognosis	10-2h	10-1
protection	10-2f	10-1
symptoms	10-2d	10-1
treatment	10-2g	10-1
Casualties		
assess dose of agent exposure	A-3d	A-2
decontamination	1-7, 1-10, 1-11, 2-6d, 2-9d, 2-16f, 3-3b, 4-6b, 4-8d, 4-19b, B-1, C-1, app D	1-2, 1-4, 1-5, 2-8, 2-11, 2-15, 3-2, 4-1, 4-6, 4-15, B-1, C-1, D-1
differential diagnosis	A-3a	A-2
emergency medical treatment	C-2—C-4	C-1
recognition of	app A	A-1
type of	A-2	A-1
Central nervous system		
depressants	3-1c	3-1

Central nervous system (<i>continued</i>)		
effects	2-4a and c, 2-5a	2-2, 2-6
stimulants	3-1c	3-1
Cerebral		
depression	4-10b(2)	4-10
edema	7-4c(1)	7-2
CG. (<i>See Phosgene.</i>)		
Chemical agents		
assess dose of agent exposure received	A-3d	A-2
classification	1-8	1-3
contamination	1-5, 1-10	1-2, 1-4
food and water	1-7	1-3
decontamination	1-7, 1-9 and -10	1-2, 1-4
definitions	1-4	1-2
detection	1-8	1-3
differential diagnosis	A-3a	A-2
exposed to	1-4, 1-6, 1-7e	1-1, 1-2, 1-3
means of delivery	1-5	1-2
military employment	1-2 and -4	1-1
persistence	preface	vi
physical characteristics	1-4	1-1
protective measures	1-7	1-2
riot control	preface	vi
routes of entry	1-3	1-1
signs and symptoms	1-7, A-3c	1-2, A-2
Chemical agent-tight containers	B-5	B-1
Chemical fire extinguishers	9-1	9-1
Chemical warfare agents	1-4, 1-8	1-1, 1-3
Chloral hydrate	3-4a	3-3
Chloroacetophenone (CN)	7-1 and -3c, 7-4c, 7-7	7-1, 7-2, 7-3
Chloropicrin (PS)	1-4a(3)	1-1
Chlorpromazine	3-4b	3-3
Choking agents. (<i>See Phosgene.</i>)		
Cholinesterase		
enzymes	2-4a, 2-19a	2-2, 2-16
inhibitor	2-1a, 2-4a and b, 2-8a, 3-4a	2-1, 2-2, 2-9, 3-3
CN and CA. (<i>See Irritant agents.</i>)		
Codeine	5-9b	5-2
Conjunctivitis	4-7a(1) and (2), 4-12a, 7-4c(1)	4-3, 4-12, 7-2
Contraindicated drugs	3-4a, 10-2g	3-3, 10-1
Convalescent care	5-10	5-3
Convulsions	2-16c, 6-5a	2-14, 6-1
Corneal involvement	4-7a(2)—(4) and b(2)(d), 4-7b(3), 4-12	4-3, 4-5, 4-12
Coughing	7-4a(1), 7-5a and c, 7-9, -13, and -15	7-1, 7-3, 7-4
Cricothyroid cannulation	9-5b(3)	9-2
Cricothyroidotomy	2-4g, 2-6f, 2-16g	2-6, 2-8, 2-15
CS. (<i>See Irritant agents.</i>)		
Curare	3-1b	3-1
CX. (<i>See Phosgene oxime.</i>)		
Cyanogen chloride (CK)		
characteristics	6-1 and -3b, 7-1	6-1, 7-1
diagnosis	6-5b, 6-6b	6-1, 6-2
pathology	6-4b	6-1
protection	6-2	6-1
treatment	6-8 and -9	6-2
Cyanosis	5-5, 6-5b, 6-10c	5-1, 6-1, 6-2
D-amphetamine	3-4c	3-3
Death	6-5b, 9-5b(1)	6-2, 9-2
Decontaminating	1-7, 1-10, app B, app D	1-2, 1-4, B-1, D-1

	Paragraph	Page
Decontaminating (<i>continued</i>)		
eyes	1-10a, 2-6d, 2-9d, 7-7a	1-4, 2-8, 2-11, 7-3
skin	1-10a, 2-6d, 2-9d, 2-16f, 3-3b, 4-2b	1-4, 2-8, 2-11, 2-15, 3-2, 4-1
Decontaminating kits, individual	app D	D-1
M258A1 Skin Decontamination Kit	1-10a	1-4
decontamination of the face, neck, ears, and other exposed skin	D-3	D-3
decontamination of the hands	D-2—D-3	D-1—D-5
M291, Skin Decontaminating Kit	1-10a	1-4
M295 Decontamination Packet, Individual Equipment (DPIE)	1-10b	1-4
Decontaminating procedures		
aprons	B-6a	B-2
casualties	1-11, 4-8d, C-1, app D	1-5, 4-6, C-1, D-1
clothing	1-10b, B-6	1-4, B-2
equipment (web, canvas, and leather)	B-6b	B-2
gloves	B-6a	B-2
litters	B-7	B-2
mask	B-6b	B-2
self	1-10, 4-26, app D	1-4, 4-17, D-1
DECON-1 WIPE	1-10	1-4
Depressant agents	3-1b and c, 3-4	3-1, 3-3
Dermatitis	7-4a(2), 7-4c(2) and -7b	7-2, 7-3
Dexamethasone sodium phosphate	5-9e	5-2
Dexamethasone sodium phosphate-neomycin ophthalmic ointment	4-7b(2)	4-3
Diagnosis of injury from toxic chemical agents	1-6, 1-8	1-2, 1-3
Diarrhea	4-10b, 4-16d, 4-21	4-10, 4-14, 4-16
Diazepam	2-6c, 2-8, 2-9e, 2-12 and -14, 2-15c and -16c	2-8, 2-9, 2-11, 2-13, 2-14
Dichloroarsines	4-17	4-14
Dichloroformoxime	4-23	4-17
Dimercaprol	4-19d	4-15
Diphenylaminochloroarsine (Adamsite) (DM)	7-9	7-4
Diphenylchloroarsine (DA)	7-9	7-4
Diphenylcyanoarsine (DC)	7-9	7-4
Disposal of contaminated clothing	4-3, C-5d	4-1, C-2
Disposition of casualties	4-5	4-1
D-lysergic acid diethylamide. (<i>See also</i> LSD.)	3-1c	3-1
DS2	B-7	B-2
Dyspnea	5-5, 5-9a, 6-5b, 7-4a(1), 7-5	5-1, 5-2, 6-1, 7-1, 7-3
Edema		
glottic	9-5b(1) and c(1)	9-2
pulmonary. (<i>See</i> Pulmonary edema.)		
Electrolyte solutions	4-10e, 4-16d	4-12, 4-14
Emphysema	5-4	5-1
Endotracheal tube	2-4g, 2-6f, 2-16g	2-6, 2-8, 2-15
Erythema, mustard	4-8	4-5
Ethylchloroarsine	4-17a	4-14
Evacuation of chemical casualties	3-2, 5-9a, 7-7c, 9-5d, C-4d(5), C-8	3-1, 5-2, 7-4, 9-2, C-2, C-3
Eye lenses, decontamination	B-6b	B-2
Eyes		
classification of eye lesions	4-7c	4-5
decontamination	1-10, 2-9d, 2-16f, 4-7b, 8-7a, 9-5d, app D	1-4, 2-11, 2-15, 4-3, 8-3, 9-2, D-1
effects of agents. (<i>See</i> specific agents.)		
injuries	1-7 and -8, 1-9, 4-29	1-3, 1-4, 4-18
treatment of eye injuries	2-9c, 2-16d, 4-7b, 4-12c, 4-17, 7-7a, 8-5e(1)	2-11, 2-15, 4-3, 4-13, 4-14, 7-3, 8-2

	Paragraph	Page
Fibrosis, pulmonary	5-9e	5-3
Firebomb		
attack	9-5c	9-2
casualties	9-5c(1)	9-2
protection	9-5c(2)	9-2
treatment	9-5a	9-2
Fire hazards	1-2d, 10-6	1-1, 10-2
Flamethrower		
attack	9-5b	9-2
casualties	9-5b(1)	9-2
protection	9-5b(2)	9-2
treatment	9-5b(3)	9-2
Fluocinolone acetonide	7-7b	7-3
Fluorescein	4-18, 4-29b(3)(a)	4-14, 4-18
Flurandrenolone	7-7b	7-3
Food, contaminated	1-7, 2-5a, 2-7c, 2-16e, 4-1d, 4-10b(1), 4-10d	1-3, 2-6, 2-9, 2-15, 4-1, 4-10, 4-12
G-agents. (See Nerve agents.)		
Genitalia, blister agent burns	4-31i	4-21
Gloves, protective	1-7, 4-3, 7-2, B-5a, B-6a, D-1	1-3, 4-1, 7-1, B-1, B-2, D-1
Granulocytopenia	4-16	4-14
Hands, blister agent burns	4-31g	4-20
HC mixture. (See Smokes.)		
HD. (See Mustard.)		
Headache	6-5a, 7-5c, 7-13	6-1, 7-3, 7-4
Hemoconcentration	4-10, 4-21	4-10, 4-16
Hemorrhagic diathesis	4-16	4-14
HN1. (See Nitrogen mustards.)		
HN3. (See Nitrogen mustards.)		
Hydrogen cyanide (AC) (hydrocyanic acid)		
characteristics	6-1 and -3a	6-1
diagnosis	6-5, 6-6	6-1, 6-2
effects	6-3a	6-1
pathology	6-4a	6-1
prognosis	6-7	6-2
protection	6-2	6-1
self-aid	6-8	6-2
treatment	6-10	6-2
Hydrogen sulfide		
occurrence in military operations	10-4b	10-2
pathology	10-4c	10-2
physical properties	10-4a	10-2
symptoms	10-4d	10-2
treatment	10-4e	10-2
Hypovolemic shock	4-10b	4-10
Hypoxemia	5-9c	5-2
Identity of chemical agents	1-8	1-3
Incapacitating agents (BZ)	3-1	3-1
decontamination	3-3b	3-2
diagnosis	3-2	3-1
first aid	3-3c	3-2
protection	3-3a	3-2
treatment	3-4	3-3
types	3-1a and c	3-1
Incendiary agents		
combustible hydrocarbons	9-5	9-2
general	9-1	9-1
magnesium	9-3	9-1
self-aid	9-4a	9-1
treatment of burns	9-2 and -4b, 9-5	9-1, 9-2
white phosphorus	9-4	9-1

	Paragraph	Page
Indoles	3-2, 3-4b	3-1, 3-3
Injector, atropine. (<i>See</i> Atropine.)		
Insecticides	2-1d	2-1
Intravenous fluids	9-5d(6)	9-3
Intubation	9-5b(3)	9-2
Iritis	4-7a(3), 4-12b, 4-18a, 4-29b, 7-7a	4-3, 4-13, 4-14, 4-18, 7-3
Irritant agents		
characteristics	7-3	7-1
diagnosis	7-5	7-3
physiological effects	7-4	7-1
prognosis	7-8	7-4
protection	7-2	7-1
self-aid	7-6	7-3
treatment	7-7	7-3
Kits		
Mark I Nerve Agent Antidote Kit	2-6, 2-9, 2-10 and -11, 2-15—18, 2-19a, 2-20b, app E	2-8, 2-11, 2-12, 2-14, 2-16, 2-17, E-1
M256 Chemical Agent Detector Kit	1-8	1-3
M258A1 Skin Decontamination Kit	1-10, B-6b, D-3	1-4, B-2, D-3
M291 Skin Decontaminating Kit	1-10a, B-6b, D-2	1-4, B-2, D-1
Lacrimators	6-3b, 7-1, -3c, and -4, 7-9	6-1, 7-1, 7-4
Lesions. (<i>See</i> Blister agents.)		
Leukopenia	4-10e	4-12
Lewisite (L) (chlorovinyldichloroarsine)	1-4a, 1-8, 4-1, 4-17	1-2, 1-4, 4-1, 4-14
Lifesaving measures	2-8a, 2-9h	2-9, 2-12
Liquid arsenical vesicants, effects of	1-4, 1-8, 4-17—4-22	1-2, 1-3, 4-14—4-16
Liquid nerve agent, effects of	2-4d	2-6
Litters		
care	B-7	B-2
decontamination	B-7	B-2
protection	B-7	B-2
Lower extremities	4-31h	4-21
LSD	3-1c, 3-2c, 3-4b—c	3-1, 3-2, 3-3
Lung irritants. (<i>See</i> Phosgene.)		
Magnesium (MG)	9-3	9-1
Marihuana	3-2b, table 3-1	3-1, 3-2
Masking	1-12b, 2-3b, 2-6a and -7, 2-9a, 2-11a, 2-12b, 3-3a, 4-25, 7-2, 7-10 and -13, 9-1b, 9-5d, B-4a, C-8	1-5, 2-1, 2-8, 2-11, 2-12, 2-13, 3-2, 4-17, 7-1, 7-4, 9-1, 9-2, B-1, C-3
Masking the odor of chemical agents	1-6a	1-2
Mass casualties	C-1	C-1
Mechanical ventilator	2-16g	2-15
Mechanism of action, nerve agents	2-4a	2-2
Medical treatment facility (MTF)	2-15, 4-3b	2-14, 4-1
Mental depression	7-5c, 7-13	7-3, 7-4
Metal decontamination	B-7b(1)(c)	B-2
Methemoglobin	10-3c	10-1
Methemoglobinemia	6-10c	6-2
Methyldichloroarsine	4-17	4-14
Methylprednisolone	5-9e(2)(c)	5-3
Military use of chemical agents	1-2, 1-4b	1-1, 1-2
Miosis	2-3a, 2-4c, 2-4d, 2-5b, 2-9c, 2-16d, 4-12a, 4-18, 4-29b(2)(a)	2-1, 2-2, 2-6, 2-8, 2-11, 2-15, 4-12, 4-14, 4-18
Mission-oriented protective posture (MOPP) level	1-7, 2-8c, 2-20d, B-4	1-2, 2-9, 2-17, B-1
Morphine	4-10b, 9-5a	4-12, 9-2
MRE pouches	4-10d	4-12
Muscarinic		
effects	2-4c(3)(a), 2-5a, 2-8a(1), 2-8c(1)(d), 2-16a	2-5, 2-8, 2-9, 2-11, 2-14

	Paragraph	Page
Muscarinic (<i>continued</i>)		
signs and symptoms	2-4a, table 2-1, 2-4c(3)(b), 2-5a, 2-13, 2-15a(1)	2-2, 2-3, 2-5, 2-8, 2-13, 2-14
Mustard (HD)		
burns	4-7b(3)	4-5
characteristics	1-4a(2), 4-6a	1-2, 4-1
conjunctivitis	4-7b(2)	4-3
decontamination	1-4, 1-10, 1-11, 4-7b(1), 4-8d	1-1, 1-4, 1-5, 4-3, 4-6
effects on the eye	1-7, 4-7	1-2, 4-2
ingestion	4-10e(2)	4-12
lesions of eyes	4-7b(2), 4-7b(3), 4-29c	4-3, 4-5, 4-19
pathology	4-7a, 4-8—4-10	4-2, 4-5—4-10
persistence	1-4, 4-6b	1-1, 4-2
prognosis	4-7a	4-2
sensitivity	4-29	4-18
symptoms	1-6 and -7, 4-7a, 4-8, 4-9, 4-10b	1-2, 4-2, 4-5, 4-9, 4-10
treatment	4-7b, 4-12c, 4-18b, 4-29	4-3, 4-13, 4-15, 4-18
vapor	1-2, 1-13, 4-6	1-1, 1-5, 4-1
M8 Detector Paper	1-8a	1-3
M9E1 Chemical Agent Detector Paper	1-8a	1-3
M17 series protective mask carrier	1-10	1-4
M24 and M25 series protective mask	1-10	1-4
M256 Chemical Agent Detector Kit	1-8c	1-4
M258A1 Skin Decontamination Kit	1-10a, 4-8d, D-3	1-4, 4-6, D-3
M291 Skin Decontaminating Kit	1-10, D-2	1-4, D-1
M295, Decontaminating Packet, Individual Equipment	1-10b	1-5
Nausea	6-5a, 7-1 and -4a(1), 7-9, -13, and -15	6-1, 7-1, 7-4
Neostigmine	3-4a	3-3
Nerve Agent Antidote Kit, Mark I, procedures for administering	2-9—2-16, app E	2-11—2-14, E-1
Nerve Agent Pyridostigmine Pretreatment Tablet Set (NAPP)	2-17—2-24	2-15—2-18
Nerve agents	1-4, 2-1 and -3	1-1, 2-1
absorption	1-6, 1-10, 2-3a, 2-7, 2-8b, 2-9	1-2, 1-4, 2-1, 2-8, 2-9, 2-11
cause of death	2-4c, 2-4g	2-2, 2-6
characteristics	1-4, 2-1—2-24	1-2, 2-1—2-18
convulsions	2-4c, 2-5b, 2-12 and -14, 2-15c, -16a, and -16c	2-2, 2-8, 2-13, 2-14
cumulative effects of repeated exposure	2-4a, 2-4f	2-2, 2-6
decontamination	1-9 and -10, 2-2 and -3c, 2-9d, 2-16f, app D	1-4, 2-1, 2-11, 2-15, D-1
diagnosis	1-6, 1-13, 2-5	1-2, 1-5, 2-6
effects of vapor	2-4c	2-2
first aid	1-12	1-5
buddy aid	1-12b, 2-5b, 2-9, 2-11, 2-12, E-3	1-5, 2-8, 2-11, 2-12, 2-13, E-4
self-aid	1-12a, 2-5b, 2-9, 2-11, 2-12, E-2	1-5, 2-8, 2-11, 2-12, 2-13, E-1
medical treatment	1-13, 2-1d, 2-4, 2-6, 2-8—2-16	1-5, 2-1, 2-2, 2-8, 2-9—2-14
physiological effects	1-4, 2-1a	1-1, 2-1
pretreatment	2-17—2-24	2-15—2-18
prevention	2-3b, 2-6 and -7, 2-12	2-1, 2-8, 2-13
protection	2-3b, 2-3d, 2-6a—2-9, 2-19a	2-1, 2-2, 2-8—2-11, 2-16
V-agent	1-4, 2-4a	1-1, 2-2
Nicotinic effects	2-4a, 2-4c	2-2, 2-5
Nitrogen mustard (HN)		
characteristics	4-11	4-12
physiological effects	1-4, 4-12—4-16	1-1, 4-12—4-14
treatment	4-12—4-16	4-12—4-14

	Paragraph	Page
Nitrous fumes		
diagnosis	10-3e	10-2
occurrence in military operations	10-3b(1) and (2)	10-1
physical properties	10-3a	10-1
physiological effects	10-3c	10-1
prognosis	10-3g	10-2
protection	10-1c	10-1
symptoms	10-3d	10-2
treatment	10-3f	10-2
Nonpersistent		
chemical agent	preface, 5-3, 6-1 and -3b	vi, 5-1, 6-1
nerve agent	2-2	2-1
Normal saline solution	7-4a(2)	7-2
Objectives of health service support	C-2	C-1
O-chlorobenzylidene malononitrile (CS)	7-1 and -3a, 7-4—7-6	7-1, 7-1—7-3
Ophthalmic ointment, atropine	4-18b	4-15
Opiates	4-16d	4-14
Oral replacement of body fluids	9-5d	9-2
Organophosphates	1-1b, 2-1d	1-1, 2-1
Oxygen therapy	2-6f, 2-16g, 5-9c, 6-10, 10-2g	2-8, 2-15, 5-2, 6-2, 10-1
Parasympathomimetic effects	4-10b(2)	4-10
Persistent		
chemical agent	preface	vi
nerve agent	preface	vi
Personal decontamination	1-10, 4-26	1-4, 4-17
Petroleum oil smoke. (See Smokes.)		
Phenothiazine-type compounds	3-1c(1)(b), 3-4a	3-1, 3-3
Phenyldichloroarsine (PD)	4-22	4-16
Phosgene (CG)		
characteristics	1-4, 5-3	1-1, 5-1
diagnosis	5-6	5-1
general	5-1	5-1
pathology	5-4	5-1
protection	5-2	5-1
self-aid	5-8	5-2
symptoms	5-5	5-1
treatment	5-8—5-10	5-2—5-3
Phosgene oxime (dichloroformoxime) (CX)		
characteristics	4-23	4-17
physiological effects	1-4, 4-1, 4-24	1-1, 4-1, 4-17
protection	4-25	4-17
treatment	4-26 and -27	4-17
Phosphoric acid derivatives	2-1a	2-1
Photophobia	4-12a, 4-29, 7-4c(1)	4-12, 4-18, 7-2
Physostigmine (salicylate)	2-1a, 3-4a	2-1, 3-3
Pneumonitis, chemical	4-14b	4-14
Pralidoxime chloride (2 PAM Cl)	2-8a(2) and b(2), 2-8c(2) and -9f, 2-10, 2-15b	2-9, 2-11, 2-12, 2-14
Prednisolone	5-9e(1)(b), 5-9e(2)(c)	5-2, 5-3
Prevention of poisoning	2-3, 2-6 and -7	2-1, 2-8
Protective		
mask		
conditions for	1-7, 2-3b, 2-6 and -7, 2-9, 2-11, 2-20d, 3-3a, 4-2, 4-25, 5-8, 6-2, 6-8b, 7-2, 7-6, 7-10 and -15, 8-2, 8-4d, -5d, and -6d, 8-7d, 10-6	1-2, 2-1, 2-8, 2-11, 2-12, 2-17, 3-2, 4-1, 4-17, 5-2, 6-1, 6-2, 7-1, 7-3, 7-4, 8-1, 8-2, 8-3, 10-2
limitations	4-4a, 9-1, 10-1c, 10-6b	4-1, 9-1, 10-1, 10-2
overgarment	1-12b, 2-3d, 2-6a, 2-9a, 4-4b, 7-2	1-5, 2-2, 2-8, 2-11, 4-1, 7-1
Pruritus	7-7b	7-3

	Paragraph	Page
Pulmonary edema	4-14a, 4-20a, 4-21c, 5-4, -5, and -6, 5-9a, 6-4 and -5b, 7-4c(1)	4-13, 4-15, 4-16, 5-1, 5-2, 6-1, 7-2
fibrosis	4-9, 5-9e(2)(c)	4-9, 5-3
parenchyma	4-30h	4-19
Pyridostigmine	2-1a, 2-17—2-24, 3-4a	2-1, 2-15—2-18, 3-3
Reactions of agents with water	1-5	1-2
Reception of contaminated casualties basic plan	C-1, -3, and -4	C-1
Respiratory system, effects on	1-6, 2-4a and c, 2-5, 4-9, 4-14, 4-20, 4-30, 9-5b(3)	1-2, 2-2, 2-6, 4-9, 4-13, 4-15, 4-19, 9-2
Resuscitation. (<i>See Assisted ventilation and Mechanical ventilator.</i>)		
Rhinorrhea	7-5a	7-3
Riot control agents	7-1—7-17	7-1—7-4
Rubber gloves	7-2a	7-1
Saprophytic bacteria	4-8b(3)	4-6
Sarin (GB)	1-4a, 2-1b	1-2, 2-1
Sedatives	4-16d, 4-19d, 5-9b	4-14, 4-15, 5-2
Self-aid		
blister (vesicant) agents	4-2	4-1
cyanogen chloride (CK)	6-8b	6-2
hydrogen cyanide (AC)	6-8a	6-2
mustard (HD)	4-2, 4-7b	4-1, 4-3
mustard (HN)	4-12	4-12
nerve agents	2-1—2-7c, 2-15 and -16, E-2	2-1—2-9, 2-14, E-1
phosgene	5-8	5-2
zinc oxide (HC) mixtures	8-4d	8-2
Shipboard operations	B-5b	B-1
Signs and symptoms of toxic agents	1-7	1-2
Silver sulfadiazine burn cream	4-8f	4-8
Skin		
blister agent lesions	1-4, 4-1, 4-8, 4-13, 4-19, 4-24, 4-31	1-1, 4-1, 4-5, 4-13, 4-15, 4-17, 4-19
decontamination	1-10, 3-3b, 4-2, 4-7b, 4-8d, 4-13c, 4-26, 7-2, 7-6, 8-6d, D-1	1-4, 3-2, 4-1, 4-3, 4-6, 4-13, 4-17, 7-1, 7-3, 8-2, D-1
Smokes, agents used		
HC mixtures	8-1 and -4	8-1
pathology	8-4b	8-1
petroleum oil (fog oil (SGF2))	8-1a and -3	8-1
physical properties	8-3a	8-1
physiological properties	8-3b	8-1
prognosis	8-4f	8-2
properties	8-4a	8-1
self-protection	8-4d	8-2
symptoms	8-4c	8-1
treatment	8-4e	8-2
sulfur trioxide-chlorosulfonic acid (FS)	8-5	8-2
pathology	8-5b	8-2
prognosis	8-5f	8-2
properties	8-5a	8-2
self-aid	8-5d	8-2
symptoms	8-5c	8-2
treatment, eye and skin	8-5e	8-2
titanium tetrachloride (FM)	8-1a, 8-6	8-1, 8-2
pathology	8-6b	8-2
prognosis	8-6f	8-3
properties	8-6a	8-2
self-aid	8-6d	8-2
symptoms	8-6c	8-2
treatment	8-6e	8-3

	Paragraph	Page
white phosphorus (WP)	8-1a, 8-7	8-1, 8-3
pathology	8-7b	8-3
prognosis	8-7f	8-3
properties	8-7a	8-3
self-aid	8-7d	8-3
symptoms	8-7c	8-3
treatment	8-7e	8-3
zinc chloride	8-1a	8-1
pathology	8-4b	8-1
properties	8-1 and -4a	8-1
protection	8-2	8-1
self-aid	8-4d	8-2
symptoms	8-4c	8-1
treatment	8-4e	8-2
Sneezing	7-9, -13, and -15	7-4
Sodium		
bicarbonate	7-4a(2)	7-2
carbonate	7-4a(2)	7-2
nitrite injections	6-10c	6-2
sulfacetimide	4-7b, 4-12	4-3, 4-12
thiosulfate	6-10	6-2
Soman (GD)	1-4, 2-1b	1-1, 2-1
Steroid treatment	5-9e	5-2
Stimulants	3-1c(2)	3-1
Sulfur trioxide-chlorosulfonic acid solution (FS)	8-1, 8-5	8-1, 8-2
Synechia	4-18a	4-14
Tabun (GA)	1-4a, 2-1b	1-2, 2-1
Tactical use of chemical agents	1-2, 1-5	1-1, 1-2
Tear agents (lacrimators)	7-1	7-1
Thermite (TH)	9-2	9-1
Time course of nerve agent effects	table 2-2	2-7
Titanium tetrachloride (FM)	8-1, 8-6	8-1, 8-2
Topical corticosteroid	7-7b	7-3
Tracheitis	7-4a(1)	7-1
Tracheotomy	9-5b	9-2
Training agents. (<i>See also</i> O-chlorobenzylidene malononitrile (CS), Chloroacetophenone (CN), <i>and</i> Bromobenzylcyanide (CA)).	7-1	7-1
Treatment of injuries caused by chemical agents. (<i>See</i> specific agents.)		
Triage	C-4b	C-1
Triamcinolone acetonide	7-7b	7-3
Trimethobenzamide hydrochloride	7-16	7-4
protective measures	1-7	1-2
riot control agents	7-6	7-3
sulfur trioxide-chlorosulfonic acid (FS)	8-5d	8-2
titanium tetrachloride (FM)	8-6	8-2
vomiting agents	7-15	7-4
white phosphorus (WP)	8-7, 9-4	8-3, 9-1
Unit medical support	C-1	C-1
Urticants. (<i>See</i> Phosgene oxime.)		
V-agents	1-4, 2-1b	1-1, 2-1
Vapor effects	1-3 and -4, 2-3a, 2-4, 2-5a, 2-7c, 2-9f, 4-9, 4-14, 4-24, 4-31, 6-3, 7-4	1-1, 2-1, 2-2, 2-6, 2-9, 2-11, 4-9, 4-13, 4-17, 4-19, 6-1, 7-2
Vertigo	6-5a	6-1
Vesicants. (<i>See</i> Blister agents.)		
Vomiting agents		
characteristics (properties)	1-6, 7-11	1-2, 7-4
diagnosis	1-6, 1-13, 7-14	1-2, 1-5, 7-4
effects	7-9, -12, and -13	7-4

	Paragraph	Page
Vomiting agents (<i>continued</i>)		
odor	1-6	1-2
pathology	7-12	7-4
prognosis	7-17	7-4
protection	1-7, 7-10	1-2, 7-4
self-aid	1-12, 7-15	1-5, 7-4
symptoms	1-6, 7-13	1-2, 7-4
treatment	1-13, 7-16	1-5, 7-4
VX	1-4, 2-1 <i>b</i>	1-1, 2-1
Water, contamination	1-7 <i>e</i> , 2-7 <i>c</i> , 2-16 <i>e</i> , 4-1 <i>d</i> , 4-10 <i>b</i>	1-3, 2-9, 2-15, 4-1, 4-10
Weather, effects	2-10 <i>c</i> , 4-6 <i>b</i> , 4-8, B-2	2-12, 4-2, 4-5, B-1
Web equipment, decontamination	B-6 <i>b</i> (2)	B-2
Wet Bulb Globe Temperature (WBGT) Index	1-7 <i>f</i>	1-3
White phosphorus (WP)	8-7, 9-4	8-3, 9-1
treatment	8-7, 9-4	8-3, 9-1
World War I statistics	4-7 <i>a</i> , 4-9 <i>a</i> (2), 4-28 <i>b</i> , 5-7	4-2, 4-9, 4-17, 5-2
World War II experience	4-28 <i>c</i>	4-17
Zinc chloride	5-9 <i>e</i> , 8-1 and -4	5-2, 8-1
pathology	8-4 <i>b</i>	8-1
properties	8-1 and -4 <i>a</i>	8-1
protection	8-2	8-1
self-aid	1-12 <i>a</i> , 8-4 <i>d</i> and -5 <i>d</i> , 8-7 <i>d</i>	1-5, 8-2, 8-3
treatment	8-4—8-7	8-2—8-3